No profile data available.
Shattuck Labs, Inc. (STTK) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Austin, United States, with about 40 full-time employees.
It reported revenue of $1.00 million for fiscal year 2025, down 82.5% from fiscal year 2024, and net income of -$48.81 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $599.17 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States.
Shattuck Labs reported $1.00 million in revenue for fiscal year 2025, down 82.5% from $5.72 million in fiscal year 2024. In Q2 2026 revenue was $0.
$599.17 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Rigel Pharmaceuticals, Inc. (RIGL), Monte Rosa Therapeutics, Inc. (GLUE), Climb Bio Inc (CLYM), Kyverna Therapeutics, Inc. (KYTX).